Compare H2O America (HTO) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Medpace Holdings Inc — how do they compare? H2O America trades at $58.54 (market cap $2.43B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 6.9× H2O America's market cap, and H2O America pays a 3.03% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Medpace Holdings Inc for 14 Days on average.
| HTO | MEDP | |
|---|---|---|
Market Cap | $2.43B | $16.82B |
Volume | 593,883 | 223,093 |
Sector | Utilities | Health |
52-Week High | $65.43 | $630.19 |
52-Week Low | $44.44 | $393.42 |
Typical Hold Time | 40 Days | 14 Days |
Enterprise Value | $4.22B | $16.44B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.70, up 1.24% with mixed technical signals showing bearish moving averages but bullish oscillators. The company maintains strong profitability with 12.91% net margins and recently completed the Quadvest acquisition through its Texas subsidiary. Analyst consensus remains strongly bullish with 83% buy ratings and a $66.50 price target, representing 13% upside potential from current levels.
The outlook appears favorable given the strategic acquisitions and Dividend King status, though execution risks from recent equity dilution and negative cash flow from investing activities warrant monitoring. The stock offers value with reasonable P/E of 20.45 and consistent earnings beats, supported by institutional accumulation including BlackRock's significant position.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
